Navigation Links
Edison Pharmaceuticals, Inc. signs licensing agreement with Dainippon Sumitomo Pharma Co., Ltd. for development & commercialization of orphan mitochondrial and adult central nervous system disease drugs
Date:3/28/2013

itical role.

The Edison redox platform consists of proprietary laboratory and clinical tools that enable the discovery, optimization, and clinical validation of redox-directed drugs. Specifically, through employing both laboratory and clinically derived redox signatures of disease and drug action, Edison is able to develop drugs at a fraction of the time and cost of current drug development processes, thereby reducing risk and cost and increasing the likelihood of success.

Edison will use proceeds derived from the partnership to advance the late stage development and commercialization of EPI-743 for Leigh syndrome and Friedreich's ataxia, as well as to advance EPI-743 in other exploratory phase 2 trials for rare pediatric diseases with shared mitochondrial mechanisms.

"Our partnership with Dainippon Sumitomo Pharma will allow Edison to accelerate the development and approval of the first drug for inherited respiratory chain diseases of the mitochondria," stated Guy Miller , MD, PhD, Chairman and CEO of Edison. "Our shared vision of the role of redox control and the mitochondria in human disease will help us extend our learnings derived from rare pediatric diseases to poorly treated acute and chronic adult CNS diseases."

EPI-743 & EPI-589
EPI-743 is an orally bioavailable small molecule being developed by Edison Pharmaceuticals for the treatment of inherited mitochondrial diseases. EPI-743 is a member of the para-benzoquinone class of drugs. It serves as a cofactor for the novel drug target– NADPH quinone oxidase 1 (NQO1). Through a redox-based mechanism, EPI-743 augments endogenous glutathione biosynthesis– essential for the control of oxidative stress. EPI-589 is a next-generation, reversible redox cofactor being developed for a varie
'/>"/>

SOURCE Edison Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Edison Pharmaceuticals & Bambino Gesu Childrens Hospital Announce Initiation of EPI-743 Phase 2 Cobalamin C Deficiency Syndrome Clinical Trial
2. Samsung Medison Showcases New Medical Equipment and Technology with Samsung Electronics at RSNA 2012
3. Edison Pharmaceuticals Closes $20M Series F Financing
4. Edison Pharmaceuticals Announces Initiation of EPI-743 Phase 2B Leigh Syndrome Clinical Trial
5. Massive Hiring Event for Life Science Professionals in Edison, NJ on 9/18/12
6. Edison Pharmaceuticals Announces Positive Results of EPI-743 Phase 2A Leigh Syndrome Clinical Trial
7. EMA Grants Orphan Designation to Edison Pharmaceuticals for EPI-743 for Treatment of Leigh Syndrome
8. Carolinas HealthCare System and Edison Nation Collaborate to Drive Medical Innovation and Technology
9. Diabecline Antibiotic Receives Edison Award for Best New Pharmaceutical Product
10. Harwood Feffer LLP Announces Investigation of Spectrum Pharmaceuticals, Inc.
11. Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Spectrum Pharmaceuticals, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... Aug. 28, 2015 Research ... of the "Investigation Report on China,s Ranibizumab Market, ... by Novartis, ranibizumab was approved by CFDA to treat ... only Lucentis, a product of Novartis, is available in ... first self- developed drug for the treatment of wet ...
(Date:8/28/2015)... , Aug. 28, 2015  Perrigo Company plc ... it has completed the acquisition of leading OTC brands ... €200 million. The transaction is a clear demonstration of ... Company,s leading European distribution network spanning 36 countries.  ... C. Papa commented, "We are excited to complete ...
(Date:8/28/2015)... PUNE, India , August 28, 2015 ... Essential Oils), Livestock (Pork/Swine, Poultry, Ruminant, and Aquaculture), & by ... , Asia-Pacific , and Rest of ... by MarketsandMarkets, The global market for Eubiotics was valued at ... USD 7.05 Billion by 2020, at a CAGR of 7.4% ...
Breaking Medicine Technology:Investigation Report on China's Ranibizumab Market, 2012-2019 2Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 2Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 3Perrigo Completes Acquisition of Leading Portfolio of OTC Brands from GSK 4Eubiotics Market Worth 7.05 Billion USD by 2020 2Eubiotics Market Worth 7.05 Billion USD by 2020 3Eubiotics Market Worth 7.05 Billion USD by 2020 4Eubiotics Market Worth 7.05 Billion USD by 2020 5
(Date:8/30/2015)... ... , ... Natural Rest contains a unique mixture of vitamins and herbs that ... help to improve mood disorders and anxiety. Like all other Creative Medical Health products, ... of regenerative medicine conducted by Dr. Amit Patel of the University of Utah, one ...
(Date:8/30/2015)... Boca Raton, Fl (PRWEB) , ... August 30, ... ... today that Executive Vice President Jeff Fernandez will lead the expansion of global ... of cosmeceutical and skin care experience having spent the last 25 years working ...
(Date:8/30/2015)... ... August 30, 2015 , ... SonaCare Medical, LLC, ... treatment of prostate cancer, has announced the roll-out of its newest technology – ... in Puerto Vallarta, Mexico. , The Sonablate® technology currently in use at the ...
(Date:8/29/2015)... ... ... On September 30, 2015, the Career and Transfer Center (CTC) at Estrella ... Colleges , will be hosting a Job Expo to provide a professional, open venue ... Expo has expanded to much more than just a typical job and career fair. ...
(Date:8/29/2015)... ... August 29, 2015 , ... On Saturday, September 19, ... Applied Research Foundation (Meso Foundation) will present an educational program titled “Asbestos and ... and lasts through 9:30 PM (doors open at 6:45pm) at Calvary United Methodist Church, ...
Breaking Medicine News(10 mins):Health News:Creative Medical Health’s Natural Rest® Now Available on ReCreative Medical Health’s Natural Rest® Now Available on RevNutrition.com 2Health News:NPI Executive Vice President Leads Cosmeceutical Expansion 2Health News:Image Fusion Technology Combines MRI and Ultrasound Images to Treat Prostate Cancer 2Health News:Estrella Mountain Community College Expo Offers ‘One-Stop’ for Employers and Students Seeking Internships, Jobs, Careers and Service Learning Opportunities 2Health News:Mesothelioma Applied Research Foundation to Hold Educational Class About Asbestos and Mesothelioma Prevention 2
... validity of Purdue patents; Receives limited license rights ... ST. LOUIS, June 9 KV Pharmaceutical Company (NYSE: ... it has entered into a settlement agreement with Purdue Pharma ... lawsuit between the two companies. Under the terms of ...
... early in the course of disease is the best approach ... acute myeloid leukemia (AML), according to a new analysis of ... published in the June 10 issue of the Journal ... Cancer Institute and other institutions, provide new guidelines for treatment ...
... , WASHINGTON, June 9 The "Blue Dog Coalition," a ... oppose a strong public option to for-profit health insurers, took ... insurance and drug industries according to Consumer Watchdog. , ... Landrieu (D-LA) now opposes the public option. Landrieu received ...
... expert says, , TUESDAY, June 9 (HealthDay News) -- ... women as their pregnancy progresses, a new Brazilian study ... to 80 percent of moms-to-be suffering heartburn, stomach pain ... worsen over time, and women who avoid taking medicine ...
... PEMBROKE, Bermuda, June 9 Allied World Assurance,Company (U.S.) ... Ltd (NYSE: AWH ), today announced an ... in the United States. The,complimentary service, called "Strategic Response(SM)," ... resources in the,event of a catastrophe. , ...
... New Dialysis Patients Making a Difference in Cutting Patient Mortality ... (NYSE: DVA ), a leading provider of kidney ... today commended Kidney Care Partners for launching the Performance Excellence ... Partners - a coalition of patient advocates, dialysis professionals, care ...
Cached Medicine News:Health News:KV Pharmaceutical Company, Purdue Pharma L.P. Settle OxyContin(R) Dispute 2Health News:KV Pharmaceutical Company, Purdue Pharma L.P. Settle OxyContin(R) Dispute 3Health News:KV Pharmaceutical Company, Purdue Pharma L.P. Settle OxyContin(R) Dispute 4Health News:KV Pharmaceutical Company, Purdue Pharma L.P. Settle OxyContin(R) Dispute 5Health News:KV Pharmaceutical Company, Purdue Pharma L.P. Settle OxyContin(R) Dispute 6Health News:Study IDs benefit of donor SCT for adults with acute myeloid leukemia 2Health News:Will Insurer & Drug Money Leash the 'Blue Dogs'? 2Health News:Will Insurer & Drug Money Leash the 'Blue Dogs'? 3Health News:Will Insurer & Drug Money Leash the 'Blue Dogs'? 4Health News: Acupuncture May Relieve Heartburn In Pregnancy 2Health News: Acupuncture May Relieve Heartburn In Pregnancy 3Health News:Allied World U.S. Announces Strategic Response(SM) - Complimentary Service Added to General Liability Lead Umbrella Product 2Health News:Allied World U.S. Announces Strategic Response(SM) - Complimentary Service Added to General Liability Lead Umbrella Product 3Health News:DaVita Commends Kidney Care Partners for Launch of PEAK Campaign 2Health News:DaVita Commends Kidney Care Partners for Launch of PEAK Campaign 3
Angled shafts with 12 mm scaled jaws. 1 mm teeth on one jaw fit into holes on the other jaw. Slide lock and serrated handle with polished finish. Right. Most popular size or model....
Angled 13.5 mm adjustable blades. Teeth in lower jaws fit into holes in upper jaws. Grooves in lower jaw for passage of suture needles. Round knurled handle with polished finish....
Straight shafts with 5.5 mm tying platform and 1 mm crisscross serrated tips. Wide serrated handle with polished finish....
Delicate # 4...
Medicine Products: